- Home
- LLY
as 06-23-2025 2:37pm EST
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
| Founded: | 1876 | Country: | United States |
| Employees: | N/A | City: | INDIANAPOLIS |
| Market Cap: | 652.7B | IPO Year: | N/A |
| Target Price: | $1014.67 | AVG Volume (30 days): | 3.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 18 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 12.29 | EPS Growth: | 80.99 |
| 52 Week Low/High: | $677.09 - $972.53 | Next Earning Date: | 08-07-2025 |
| Revenue: | $49,003,200,000 | Revenue Growth: | 36.38% |
| Revenue Growth (this year): | 33.05% | Revenue Growth (next year): | 19.39% |
Latest Eli Lilly and Company News
LLY Breaking Stock News: Dive into LLY Ticker-Specific Updates for Smart Investing
Reuters
2 days ago
Lilly expects orforglipron obesity results in third quarter
PR Newswire
2 days ago
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
MT Newswires
3 days ago
S&P 500 Edges Down Weekly as Declines Led by Health Care Outweigh Energy-Led Gains
MT Newswires
3 days ago
Sector Update: Health Care Stocks Retreat Late Afternoon
Reuters
3 days ago
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
Barchart
3 days ago
A $1.3 Billion Reason to Buy Eli Lilly Stock Now
MT Newswires
3 days ago
Sector Update: Health Care Stocks Softer in Afternoon Trading
MT Newswires
3 days ago
Sector Update: Health Care
Compare LLY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LLY Eli Lilly and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.